echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Top 10 best selling tumor drugs in the world in 2018

    Top 10 best selling tumor drugs in the world in 2018

    • Last Update: 2019-04-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Gen (Journal of genetic engineering and biotechnology News) released the top ten best-selling antitumor drugs in 2018 on Monday In the pharmaceutical industry, it is traditionally used to use the term "blockbuster drugs" as a benchmark to consider whether a drug can enter the elite drug echelon in the history of medicine The definition of "blockbuster drugs" is that the annual sales volume exceeds 1 billion US dollars After the self weight bomb strategy has become a consensus in the industry, multinational pharmaceutical companies have developed or acquired one by one heavy bomb drugs to achieve large-scale expansion, maintain competitive strength, and obtain huge profits to meet the huge investment in follow-up research and development and the expectations of investors The world's first "heavy bomb drug" is GSK's shanweide, which achieved an annual sales volume of more than US $1 billion in 1986 Among the anti-tumor drugs, paclitaxel was the first to reach the standard of heavy bomb drug, which was achieved in 1997 Today, more than 20 years later, the expenditure on cancer treatment has been another scene According to iqvia's global trend of cancer drugs in 2018, the global expenditure on cancer drugs continues to increase In 2017, the total expenditure reached 133 billion US dollars, higher than the 96 billion US dollars in 2013 The price of new anti-tumor drugs has increased year by year The first 35 drugs account for 80% of the expenditure According to gen, the United States Two thirds of the growth in China's anti-cancer drug sales came from the introduction of anti-tumor drugs in the past five years, with 14 new anti-tumor drugs launched in 2017 alone Iqvia forecasts that, based on the annual growth rate of 12% - 15, the sales of anti-cancer drugs in the United States is expected to double again to reach 100 billion US dollars by 2022, and the growth rate of 10% - 13% in other regions of the world will eventually reach this value Therefore, three years later, the global anti-tumor drug market will reach 200 billion US dollars In 2018, the total sales of the top 10 anti-tumor drugs reached US $63.58 billion, an increase of 17.5% compared with us $54.126 billion in 2017 Among them, 7 have maintained a year-on-year growth, and 6 have even reached double-digit growth Here is the list of ten best-selling anti-tumor drugs listed by Gen in 2018 (with a comparison of sales in 2018 and 2017, unit: US $100 million): In addition, the 11th to 15th place were Wanke of Janssen / Takeda, jiekewei of Novartis / Incyte, pajite of Roche, jiadaxiu of mosadong and Zeke of Janssen The sales of these drugs in 2018 ranged from $2274 to $3498 million.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.